首页> Clinical nuclear medicine> Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.

导出原文传递

翻译打印收藏纠错

第一作者： Pierre,Sesques

第一单位： Departments of Nuclear Medicine.

作者： Pierre,Sesques ^[1] ; Jérémie,Tordo ^[2] ; Emmanuelle,Ferrant ^[2] ; Violaine,Safar ^[3] ; Florent,Wallet ^[2] ; Anthony,Dhomps ^[4] ; Gabriel,Brisou ^[4] ; Fadhela,Bouafia ^[2] ; Lionel,Karlin ^[2] ; Dana,Ghergus ^[2] ; Camille,Golfier ^[2] ; Helène,Lequeu ^[5] ; Anne,Lazareth ^[2] ; Marlène,Vercasson ^[6] ; Carole,Hospital-Gustem ^[7] ; Vérane,Schwiertz ^[7] ; Marion,Choquet ^[8] ; Pierre,Sujobert ^[9] ; Silvana,Novelli ^[10] ; Valérie,Mialou ^[10] ; Olivier,Hequet ^[11] ; Sylvain,Carras ^[12] ; Ludovic,Fouillet ^[1] ; Laure,Lebras ; Yann,Guillermin ; Cécile,Leyronnas ; Doriane,Cavalieri ; Marc,Janier ; Hervé,Ghesquières ; Gilles,Salles ; Emmanuel,Bachy

作者单位： Departments of Nuclear Medicine. ^[1] From the Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite. ^[2] Critical Care. ^[3] Claude Bernard Lyon 1 University, Lyon. ^[4] Pharmacy. ^[5] INSERM U1052 and CNRS UMR5286, Lyon Cancer Research Center, Lyon. ^[6] Department of Biology and Therapy, Etablissement Français du Sang Auvergne-Rhône-Alpes. ^[7] Department of Haematology, Grenoble University Hospital, Grenoble. ^[8] Department of Haematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne. ^[9] Department of Haematology, Centre Léon Bérard, Lyon. ^[10] Department of Haematology, Groupe Hospitalier Mutualiste, Institut Daniel Hollard, Grenoble. ^[11] Department of Haematology, Clermont Ferrand University Hospital, Clermont Ferrand, France. ^[12]